Wikipedia -WSS

Wikipedia

author：hotspot 2025-10-01 21:48:14 - browse：77

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： A new crop of companies is reshaping the health data economy

WSS

A new crop of companies is reshaping the health data economy

Study: Why relieving medical debt did not improve financial outcomes

Lilly's Alzheimer's drug donanemab backed by FDA advisers

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Search called off for baby washed away in Pennsylvania flash flood

Statins may not be needed by millions of people, study suggests

focus

Wikipedia

hotspot

Activists slam private health insurers over coverage restrictions

Curing rare childhood diseases will falter unless Congress steps up

Medicare proposal to cover medical devices draws a mixed reaction

Study: Why relieving medical debt did not improve financial outcomes

George Santos makes 1st court appearance after pleading not guilty to 13 counts

New report analyzes digital physical therapy solutions' effectiveness

Walensky prepares to leave CDC — and Congress — behind

Cigna wins case to block Amy Bricker's move to CVS

In Memoriam: Notable people who died in 2023

Why patients can’t get everything they want on drug pricing

hotspot

A new crop of companies is reshaping the health data economy

Moderna says combo Covid

Medical device trials still don't enroll enough women, study finds

Biden warns of ‘dark winter’ during final presidental debate

What causes rare myocarditis in young men after Covid vaccines?

ALS patient reclaims some autonomy thanks to wearable 'robot'

leisure time

knowledge

focus

hotspot